Hologic ( (HOLX) ) has released its Q2 earnings. Here is a breakdown of the information Hologic presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hologic, Inc. is a medical technology company specializing in women’s health, offering diagnostic, surgical, and medical imaging solutions. In its second quarter of fiscal 2025, Hologic reported revenue of $1,005.3 million, slightly exceeding its guidance. The company achieved a non-GAAP diluted EPS of $1.03, at the high end of its guidance, although it reported a GAAP diluted EPS loss of $0.08 due to significant impairment charges.
Key financial metrics reveal a 1.2% decline in revenue compared to the previous year, with diagnostics revenue showing a modest increase of 0.8%, driven by molecular diagnostics. However, breast health revenue saw a decline of 7.4%, impacted by lower sales of mammography equipment. The company also repurchased 3 million shares for $200 million, reflecting its commitment to returning value to shareholders.
Despite the challenges, Hologic’s surgical revenue grew by 4.2%, supported by the acquisition of Gynesonics and strong international sales. The company’s operating margin and net margin were adversely affected by impairment charges, but its non-GAAP gross margin improved slightly to 61.1%.
Looking ahead, Hologic maintains its annual revenue guidance but has adjusted its EPS guidance downward due to tariffs and geopolitical conditions. The company remains focused on leveraging its strengths in diagnostics and surgical innovations to drive future growth.